IGHG3 and glioblastoma: Importantly, in this fully immunocompetent model, OV-A4-IgG3 also significantly prolongs the survival of experimental mice when compared to OV-Q1 without expressing an antibody but is less effective than OV-A4-IgG2b in treating GBM.